Status: Recruiting
Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of multi-antigen cytomegalovirus (CMV)-modified vaccinia ankara vaccine and to see how well it works in treating pediatric patients with positive cytomegalovirus who are undergoing donor stem cell transplant. Multi-antigen CMV-modified vaccinia ankara vaccine may help people resist CMV life-threatening complications.
Participants needed: 80
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: City of Hope Medical CenterUpdated: Oct 6, 2025Locations: 1
Eligibility criteria
All subjects (or their guardians) must have the ability to understand and the wi... [+8]
TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT) [+15]